Summary
Background Essential hypertension patients who utilized a new digital therapeutics (DTx) application for hypertension for up to 6 months achieved notable decreases in ambulatory, home, and office blood pressures, per the HERB-DH1 randomized controlled trial. Nevertheless, the extent of its effectiveness in clinical settings is not yet fully understood. This study seeks to evaluate blood pressure changes among the initial 1,000 hypertensive patients prescribed the DTx app in a practice-based real-world data (RWD) cohort.
Methods Deidentified data from the CureApp HT clinical information database was examined. The primary outcome measure evaluated the difference in morning systolic blood pressure (SBP) at home between week 12 and baseline. Variations in morning home SBP from week 24 (measured from baseline) and app engagement rates from weeks 12 and 24 (measured from baseline) were significant secondary outcomes. We also used analysis of covariance to compare home morning SBPs between the RWD cohort and the historical HERB-DH1 control group.
Findings The practice-based RWD cohort had a mean age of 54·8 ± 11·6 years, and 48·9% of them were female. Their baseline morning home SBP was 132·8 ± 12·9 mmHg, and 91·7% of them used the app. At week 12, their morning home SBP decreased by −4·9 mmHg (confidence interval (CI), −5·6 to −4·2), and at week 24, it dropped by −6·1 mmHg (CI, −7·3 to −5·0). These declines were much greater than those seen in the HERB-DH1 control group. Subgroup analysis showed pragmatic SBP reductions with DTx in patients aged 265 years or on medication at baseline, a cohort previously excluded from the HERB-DH1 trial.
Interpretation The initial 1,000 hypertensive patients prescribed the DTx app showed significant decreases in morning home SBP. These results may suggest importance of the DTx app’s engagement and effectiveness that could extend to older adult patients and those on medication.
Funding CureApp, Inc.
Competing Interest Statement
AN was received research grants and honoraria from CureApp. YT is a CureApp employee and may own stock. TT is one of the CureApp's board members and may own stock. KN and KK received advisory board fees and honoraria from CureApp. MT has nothing to disclose.
Funding Statement
This study was supported by CureApp, Inc. (Tokyo, Japan).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Review Board of Kanazawa University's Medical Ethics Committee
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos